Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFM13 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Affimed
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AFM13 + pembrolizumab is a combination therapy under clinical investigation for relapsed or refractory Hodgkin lymphoma. **AFM13** is a bispecific, tetravalent innate immune cell engager antibody targeting CD30 on lymphoma cells and CD16A on natural killer cells and macrophages, thus promoting tumor cell killing through innate immunity. **Pembrolizumab** (brand name Keytruda; code name MK-3475) is a monoclonal antibody acting as an immune checkpoint inhibitor by targeting programmed death-1 (PD-1) to release T-cell mediated antitumor activity. The combination leverages both innate (NK/macrophage) and adaptive (T cell) immune responses for enhanced efficacy. In phase 1b studies, the therapy was well-tolerated with high overall and complete metabolic response rates, especially at the highest dose cohort[1][2][3][5].
- Other names
- AFM13 plus pembrolizumabAFM-13 plus pembrolizumabAFM 13 plus pembrolizumabAFM13 + Keytruda
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD30 (CD30 antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on AFM13 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFM13 + pembrolizumab.